The critical role of dysregulation of antioxidant activity and carbohydrate metabolism in celiac disease

Ensieh KhalKhal1, Mostafa Rezaei-Tavirani1, Mohammadreza Razzaghi2, Sina Rezaei-Tavirani3, Hakimeh Zali4, Mohammad Rostamii-Nejad5

1Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4Proteomics Research Center, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

ABSTRACT

Aim: Identification of the important processes and the related genes that are dis-regulated in the celiac disease (CD) was the aim of this study.

Background: Celiac disease is an autoimmune disorder which is characterized by immune reaction response mostly to wheat gluten. The gluten-free diet is the best-known treatment of the patients.

Methods: Significant differentially expressed proteins (DEPs) related to the CD are extracted from a published proteomics study and are included in protein-protein interaction PPI network analysis by Cytoscape software and its applications. The central proteins and related processes are identified and discussed.

Results: Among 53 queried genes, 51 individuals were recognized by the database, and after network construction, 48 ones included in the network, and three genes remained as isolated nodes. Following 50 neighbors, the network was analyzed, and eight central genes were identified as dis-regulated elements. Related processes and the role of the central genes in celiac are discussed in detail.

Conclusion: CAT, ENO1, PCK2, ACO2, ALDOOB, GALM, ADA, and ACTBADA as critical genes and Antioxidant activity, carbohydrate metabolism, inflammation, cell growth processes are highlighted as the dis-regulated individuals in CD.

Keywords: Celiac disease, Anti-oxidant, Metabolism, Inflammation, Cell growth.

(Please cite as KhalKhal E, Rezaei-Tavirani M, Akbari Z, Rezaei-Tavirani S, Zali H, Rostamii-Nejad M. The critical role of dysregulation of antioxidant activity and carbohydrate metabolism in celiac disease. Gastroenterol Hepatol Bed Bench 2019;12(4):340-347).

Introduction

Celiac disease, an autoimmune disease, is caused by an immune reaction response to wheat gluten or related rye and barley proteins in genetically susceptible individuals. Both genetic (human leukocyte antigen genes (HLA-DQ2 or HLA-DQ8)) and environmental factors (gluten) play a crucial role in its pathogenesis (1). The patients with this condition may present extremely polymorphic clinical manifestations, of which the most typical is chronic enteritis and malabsorption to diarrhea with weight loss (2). Osteoporosis, vitamin and mineral deficiencies, iron deficiency, and bone disease are the condition of the others that the patients may experience due to nutrition deficiency (3). Only accepted therapy for CD that most individuals respond to it is a permanent gluten-free diet (GFD) (4). Until fairly recently, the CD was regarded as
rare, but recent screening studies have revealed the prevalence to be as high as 1–2% in the population (5-8).

Diagnosing CD is mainly based on the specific serological tests and the presence of a characteristic enteroopathy in an intestinal biopsy (9, 10). Although specific serological tests are developed intestinal biopsy is still considered necessary for diagnosing, on the other hand, a certain level of expertise and skill for the assessment of intestinal biopsies is required, and variability in sample quality and subjective interpretation can affect on the diagnostic accuracy (11). With these diagnosis problems, earlier and reliable diagnoses for screening population is required. To achieve early diagnosis and therapy of celiac disease, detection of proteins involved in disease pathways and introducing drug targets are needed. However Several approaches such as proteomics, genomics, metabolomics, and microarray-based techniques can identify such novel celiac diagnostic biomarkers and proteins but protein-protein interaction (PPI) network analysis can be useful for detection many unknown molecular aspects of complex CD, understanding of biological processes, organization, functions of proteins, and the pathogenesis of CD, so some new diagnostic biomarkers can be introduced by study protein interaction networks (12-14).

In this study, selected proteins merely from proteomics studies are analyzed based on the GO and PPI examination to introduce some related molecular biomarkers as a panel for celiac disease.

**Methods**

Differentially expressed genes (DEGs) related to the CD were obtained from the proteomics documents published by Simula MP et al. (15). As it is shown in tables 1 and 2, 10 up-regulated and 43 down-regulated genes were selected to include in-network creation. The network was constructed via physical interaction by STRING database application of Cytoscape software 3.7.1 (16). Since default confidence score of string was .04, the median score; 0.5, was considered. Fifty related first neighbors from STRING database were added to query genes to elevate interactions between the nodes. The main connected component was analyzed by Network analyzer to determine centrality parameters.

### Table 1. List of 10 up-regulated proteins related to CD

| R | Protein name | Gene name |
|---|--------------|-----------|
| 1 | kininogen-1  | KNG1      |
| 2 | serum amyloid P-component | SAP |
| 3 | ATP synthase β chain | ATP5F1B |
| 4 | enolase α acidic | Enol |
| 5 | Proteasome subunit α type-6 | PSMA6 |
| 6 | actin | ACT |
| 7 | galectin-10 | CLC |
| 8 | Ig mu chain C region | IGGM |
| 9 | Elongation factor 2 | EF1B |
| 10 | Tryptophanyl-tRNA synthetase | WARS |

### Table 2. List of 43 down-regulated proteins related to CD

| R | Pr name ( down ) | Gene name |
|---|------------------|-----------|
| 1 | retinol-binding protein 4 | RBP4 |
| 2 | β2-glycoprotein 1 | APOH |
| 3 | Vitronectin | VTN |
| 4 | Phosphoenolpyruvate carboxykinase | PCK1 |
| 5 | 3-hydroxy-3-methylglutaryl-CoA synthase 2 | HMGC52 |
| 6 | Medium-chain specific acyl-CoA dehydrogenase | ACADM |
| 7 | Fatty Acid-Binding Protein 1 | FABP1 |
| 8 | Fatty acid-binding protein 2 | FABP2 |
| 9 | Apolipoprotein C-III | APOC3 |
| 10 | Phosphoenolpyruvate carboxykinase 2 | PCK2 |
| 11 | Carbonyl reductase (NADPH) 1 | CBR1 |
| 12 | retinol-binding protein 2 | RBP2 |
| 13 | carbamoyl-phosphate synthase | CPS1 |
| 14 | Ornithine aminotransferase | OAT |
| 15 | Aminocylase-1 | ACY1 |
| 16 | Ornithine carbamoyltransferase | OTC |
| 17 | DnaJ homolog subfamily B member 11 | DNAJB11 |
| 18 | Fructose biphosphatase aldolase B | ALDOB |
| 19 | Aldose 1-epimerase | GALM |
| 20 | Fructose-1,6-bisphosphatase | FBP1 |
| 21 | Aflatoxin B1 aldehyde reductase member 3 | AKR7A3 |
| 22 | Aldo-keto reductase family 1 member B10 | AKR1B10 |
| 23 | Glycerol-3-phosphate dehydrogenase | GPD2 |
| 24 | Hydroxyacyl-coenzyme A dehydrogenase | HADH |
| 25 | Dihydroxyacetone kinase | DAK |
| 26 | Aconitate hydratase | ACO2 |
| 27 | Cytochrome b5 | CYB5A |
| 28 | Catalase | CAT |
| 29 | Sulfotransferase 1A3/1A4 | SULT1A4 |
| 30 | Glutathione S-transferase A1 | GSTA1 |
| 31 | GTP-binding nuclear protein Ran | RAN |
| 32 | Phosphatidylethanolamine-binding protein 1 | PEBP1 |
| 33 | Hypothetical protein MGC29506 | MZBI |
| 34 | Peroxiredoxin-4 | PRDX4 |
| 35 | Villin 1 | VILI |
| 36 | Lamin-A/C | LMNA |
| 37 | Actin beta | ACTB |
| 38 | Actin-related protein 2/3 complex subunit 2 | ARP2 |
| 39 | Guanine deaminase | GDA |
| 40 | Adenosine deaminase | ADA |
| 41 | Purine nucleoside phosphorylase | PNP |
| 42 | Calcium-activated chloride channel regulator 1 | CLCA1 |
| 43 | Voltage-dependent anion-selective channel protein 1 | VDAC1 |
10% of top queried based on degree value, and also betweenness centrality was selected as hubs and bottlenecks respectively. The conventional hubs and bottlenecks were introduced as hub-bottlenecks nodes. Description of hubs and bottlenecks were searched via STRING databases and edited to show brief descriptions. To obtain clear relationships between the hubs and bottlenecks, their connections with their neighbors were separately investigated in the STRING database. The interaction between the genes was illustrated.

Results
Fifty-three significant DEGs related to celiac patients were considered to construct a PPI network. Except for two genes, the other ones were recognized STRING plugin of Cytoscape software. Weak interactions characterized the network. Therefore, fifty neighbors were added to the queried genes. Since three genes were isolated, the main connected component, including 98 nodes, was created (see figure 1). About 10% of queried nodes based on the top value of degree were selected as hubs. The hub nodes and their descriptions are tabulated in table 3. As it is shown in table 4 the bottlenecks similar to the hubs are identified based on BC. Since catalase is the top hubs of query genes and also plays a role as hub-bottleneck in the network, its subnetwork including CAT and its ten neighbors is illustrated in figure 2.

Discussion
A proteomic study of diseases provides useful information about the molecular mechanism of disorders which can be used in medical fields. In this regard, a large amount of data is available that can be a screen to find the most important ones (17). In a proteomic study, it is possible that above 1000 DEGs or proteins be identified (18). On the other hand, PPI interaction is a useful method to screen a large number of data to highlight the limited significant individual (19). In the present research, 53 DEGs related to CD are analyzed via this method. Results indicate that 8 of...
them including CAT, ENO1, PCK2, ACO2, ALDOOB, GALM, ADA, and ACTB ADA play a crucial role in CD.

It is reported that imbalance of oxidative defense system is occurred in CD due to enzymatic and non-enzymatic anti-oxidant activities. Catalase, as an anti-oxidant enzyme, plays a significant role in healthy people. Researchers confirm deficiency of catalase activity. As like catalase, it is shown SOD activity is decreased (20). In the present investigation, catalase as a down-regulated protein is introduced as a potent hub bottleneck. SOD is related to CAT in figure 2 as its neighbors.

Mitochondrial Phosphoenolpyruvate carboxykinase (PCK2) involved in the anti-inflammatory PPAR signaling pathway and downregulates in CD concerning healthy control. PPAR signaling pathway plays roles primarily in fatty acid oxidation and lipid metabolism, and secondary inflammation, and neoplastic transformation, adipogenesis, and glucose control. In the CD disease, the down-regulation of PPAR pathway could also contribute to the down-regulation of proteins involved in fatty acid and sugar metabolism observed in CD patients and direct association with the accumulation of the toxic gliadin p31-34 peptide into the cells (15, 21-24).

Table 3. Five hubs of the queried genes are presented. * CAT and ALDOB are hub-bottleneck nodes. Descriptions are derived from STRING database. BC and CC refer to betweenness centrality and closeness centrality respectively.

| name  | description                                                                 | Degree | BC  | CC  |
|-------|-----------------------------------------------------------------------------|--------|-----|-----|
| CAT   | It is described in table 4                                                  | 59     | 1.00| 0.71|
| ENO1  | 2-phospho-D-glycerate hydro-lyase; Multifunctional enzyme that, as well as its role in glycolysis, plays a part in various processes such as growth control, hypoxia tolerance and allergic responses. May also function in the intravascular and pericellular fibrinolytic system due to its ability to serve as a receptor and activator of plasminogen on the cell surface of several cell-types such as leukocytes and neurons | 49     | 0.00| 0.66|
| PCK2  | Phosphoenolpyruvate carboxykinase [GTP], mitochondrial; Catalyzes the conversion of oxaloacetate (OAA) to phosphoenolpyruvate (PEP), the rate-limiting step in the metabolic pathway that produces glucose from lactate and other precursors derived from the citric acid cycle. | 43     | 0.00| 0.63|
| ACO2  | Aconitate hydratase, mitochondrial; Catalyzes the isomerization of citrate to isocitrate via cis-aconitate. | 40     | 0.00| 0.60|
| ALDOB | It is described in table 4                                                  | 38     | 0.50| 0.61|

Table 4. Five bottlenecks among the queried genes are shown. Descriptions are derived from STRING database.

| name  | description                                                                 | Degree | BC  | CC  |
|-------|-----------------------------------------------------------------------------|--------|-----|-----|
| CAT*  | Catalase; Occurs in almost all aerobically respiring organisms and serves to protect cells from the toxic effects of hydrogen peroxide. Promotes growth of cells including T-cells, B-cells, myeloid leukemia cells, melanoma cells, mastocytoma cells and normal and transformed fibroblast cells; Belongs to the catalase family. | 59     | 1.00| 0.71|
| GALM  | Galactose mutarotase (aldose 1-epimerase); Mutarotase converts alpha-aldose to the beta-anomer. It is active on D-glucose, L-arabinose, D-xyllose, D-galactose, maltose and lactose (By similarity). | 16     | 0.50| 0.51|
| ADA   | Adenosine aminohydrolase; Catalyzes the hydrolytic deamination of adenosine and 2- deoxyadenosine. Plays an important role in purine metabolism and in adenosine homeostasis. Modulates signaling by extracellular adenosine, and so contributes indirectly to cellular signaling events. Acts as a positive regulator of T-cell coactivation, by binding DPP4. Its interaction with DPP4 regulates lymphocyte- epithelial cell adhesion. Enhances dendritic cell immunogenicity by affecting dendritic cell costimulatory molecule expression and cytokines and chemokines secretion (By similarity). Enhances CD4+ T-cell differentiation and proliferation. Acts as a positive modulator of adenosine receptors ADORA1 and ADORA2A, by enhancing their ligand affinity via conformational change. Stimulates plasminogen activation. Plays a role in male fertility. Plays a protective role in early postimplantation embryonic development (By similarity); Adenosine deaminase family | 15     | 0.50| 0.54|
| ACTB  | Actin, cytoplasmic 1; Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells. | 37     | 0.50| 0.61|
| ALDOB*| Aldolase, fructose-bisphosphate B | 38     | 0.50| 0.61|
Aldolase B (ALDOB) is involved in metabolic pathways, Sugar metabolism, and ion transport mediators. It is down-regulated in CD patients in comparison to control group (15, 25). Deficiency of aldolase B causes hereditary fructose intolerance (HFI) and many HFI patients also affect by CD, in the other hand there is a high prevalence of CD in HFI, so there is a link between HFI and CD (26, 27).

Aldose 1-epimeras (GALM) that is known mutarotase, is a crucial enzyme of carbohydrate metabolism that catalyzes the inter-conversion of the α- and β- anomers of hexose sugars such as glucose and galactose (28). Although GALM maintains the anomeric equilibrium of galactose; it plays a role in the metabolism of glucose and other sugars, and it may involve in the transport of glucose into cells (29). When GALM is inhibited, glucose reabsorption and oxidation will be blocked (30). Glucose increases in CD (31) and GALM down-regulation has occurred with respect to healthy control (15). It can be concluded that by decreasing GALM, glucose oxidation and

Figure 2. A subnetwork of CAT and its 10 neighbors is shown. Types of edges are presented in the bottom of figure.
transportation into cells will reduce. Following, the glucose concentration in the blood increases (31).

Actin beta (ACTB) is one of the two non-muscular cytoskeletal actions which it is involves in cell motility, structure, integrity, and intercellular signaling and plays critical roles in a wide range of cellular processes; including cell migration, cell division, embryonic development, and the regulation of gene expression(32-34). The common symptoms in children CD are growth failure, weight loss, short stature, and delayed puberty. Growth failure can be due to malabsorption that is in CD (35, 36). Growth deceleration results from a decline in both the rate of cell proliferation (hyperplasia) and cell enlargement (hypertrophy). In early juvenile life, body growth is primarily due to cell proliferation, leading to an increase in cell number (37, 38). Growth means getting larger, and for multicellular organisms, this is accomplished by making more cells. Cell division makes new cells to grow and also to replace old dead cells. In children, not adult, when cell division decreases, growth is reduced. It can be concluded, and cell division decreases because down-regulation of actin beta in CD patients in comparison to control group (15) and the following growth is a failure.

Adenosine deaminase (ADA) is involved in Purine metabolism (39) and the development and maintenance of the immune system. ADA downregulation is occurred in CD patients in comparison to control group (15) following adenosine increases in CD so high levels of adenosine can exacerbate inflammation responses rather than suppressing them (40). Low levels of ADA have also been associated with pulmonary inflammation, thymic cell death, and defective T-cell receptor signaling (41, 42).

Mitochondrial aconitate hydratase (AC2) is involved in Energy production and catalyzes citrate to isocitrate in the tricarboxylic acid cycle. AC2 is downregulated in CD (15). When AC2 decreases, citrate accumulates. High concentrations of cytosolic citrate can inhibit glycolysis and ATP production (43) then glucose oxidation and ATP producing will reduce. Following, the glucose concentration in the blood increases (31).

Enolase (ENO1), also known as phosphopyruvate hydratase, is involved in the glycolytic pathway and inflammatory process (44, 45). ENO1 level is higher in CD patients in comparison to control group (46).

Besides, ENO was previously associated with human diseases (46-49). Its inhibitors have been investigated as potential treatments for cancer and infectious diseases (50).

During the inflammatory process, enolase might be a substrate of caspase-1. Glycolysis is essential for macrophage survival and activation, reduction of glycolysis results from the cleavage of ENO1 and the glycolysis substrates, it seems to be an essential step toward cell death (44, 45)

In pediatric patients, such as celiac disease the autoantibodies which are directed against enolase, are present in different inflammatory conditions. The B cells activation against enolase could be a systemic event (51). Antioxidant activity, carbohydrate metabolism, inflammation, cell growth, and the related genes are the important processes which are dis-regulated in CD. It seems that focus on expression change of CAT, ENO1, PCK2, ACO2, ALDOOB, GALM, ADA, ACTBADA may be a key point in CD researches.

Acknowledgment
This study is supported by Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Conflict of interests
The authors declare that they have no conflict of interest.

References
1. Green PH, Cellier C. Celiac disease. N Engl J Med 2007;357:1731-43.
2. Corrao G, Corazza GR, Bagnardi V, Brusco G, Ciacci C, Cottone M, et al. Club del Tenue Study Group. Mortality in patients with coeliac disease and their relatives: a cohort study. Lancet 2001;358:356-61.
3. Hershko C, Hoffbrand AV, Keret D, Souroujon M, Maschler I, Monselise Y, et al. Role of autoimmune gastritis, Helicobacter pylori and celiac disease in refractory or unexplained iron deficiency anemia. Haematologica 2005;90:585-95.
4. Farrell RJ, Kelly CP. Celiac sprue. N Engl J Med 2002;346:180-8.
5. Fasano A, Berti I, Gerarduzzi T, Not T, Colletti RB, Drago S, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Int Med 2003;163:286-92.
6. Miki M, Mustalhti K, Kokkonen J, Kulmala P, Haapalahti M, Karttunen T, et al. Prevalence of Celiac disease among children in Finland. N Engl J Med 2003;348:2517-24.

7. Lohi S, Mustalhti K, Kaukinen K, Laurila K, Collin P, Rissanen H, et al. Increasing prevalence of coeliac disease over time. Aliment Pharmacol Ther 2007;26:1217-25.

8. Mustalhti K, Catassi C, Reunanen A, Fabiani E, Heier M, McMillan S, et al. The prevalence of celiac disease in Europe: results of a centralized, international mass screening project. Ann Med 2010;42:587-95.

9. Green PH, Rostami K, Marsh MN. Diagnosis of coeliac disease. Best Pract Res Clin Gastroenterol 2005;19:389-400.

10. Fasano A, Catassi CJG. Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum. Gastroenterology 2001;120:636-51.

11. Ladas SD, Tsamouri M, Kouvidou C, Raptis SA. Effect of forceps size and mode of operation on endoscopic small bowel biopsy evaluation. Gastroint Endosc 1994;40:51-5.

12. Rhodes DR, Tomlins SA, Varambally S, Mahavinson V, Barrette T, Kalyana-Sundaram S, et al. Probabilistic model of the human protein-protein interaction network. Nat Biotechnol 2005;23:951-9.

13. Gandhi T, Zhong J, Mathivanan S, Karthick L, Chandrika K, Mohan SS, et al. Analysis of the human protein interactome and comparison with yeast, worm and fly interaction datasets. Nat Genet 2006;38:285-93.

14. Azodi MZ, Peyvandi H, Rostami-nejad M, Safaei A, Rostami K, Vafaee R, et al. Protein-protein interaction network of celiac disease. Gastroenterol Hepatol Bed Bench 2016;9:268-277.

15. Simula MP, Cannizzaro R, Canzonieri V, Pavan A, Maiero S, Toaffoli G, et al. PPAR signaling pathway and cancer-related proteins are involved in celiac disease-associated tissue damage. Mol Med 2010;16:199-209.

16. Rezaei-Tavirani M, Rezaei-Tavirani M, Azodi MZ. The bioinformatics aspects of gene screening of HT-29, human colon cell line treated with caffeic acid. Gastroenterol Hepatol Bed Bench 2019;12:246-53.

17. Rezaei-Tavirani S, Rostami-nejad M, Montazar F. Highlighted role of VEGFA in follow up of celiac disease. Gastroenterol Hepatol Bed Bench 2019;12:254-259.

18. Ishihama Y, Oda Y, Tabata T, Sato T, Nagasu T, Rappsilber J, et al. Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol Cell Proteomics 2005;4:1265-72.

19. Jeong H, Mason SP, Barabási A-L, Oltvai ZN. Lethality and centrality in protein networks. Nature 2001;411:41.
36. Troncone R, Kosova RJ. Short stature and catch-up growth in celiac disease. Science 2010;51:S137-8.

37. Jorgensen P, Tyers MJCb. How cells coordinate growth and division. Curr Biol 2004;14:R1014-27.

38. Winick M, Noble AJ. Quantitative changes in DNA, RNA, and protein during prenatal and postnatal growth in the rat. Dev Biol 1965;12:451-66.

39. Losey HC, Ruthenburg AJ, Verdine GL. Crystal structure of Staphylococcus aureus tRNA adenosine deaminase TadA in complex with RNA. Nat Struct Mol Biol 2006;13:153-9.

40. Moriwaki Y, Yamamoto T, Higashino KJH, histopathology. Enzymes involved in purine metabolism—a review of histochemical localization and functional implications. Histol Histopathol 1999;14:1321-40.

41. Blackburn MR, Kellems RE. Adenosine deaminase deficiency: metabolic basis of immune deficiency and pulmonary inflammation. Adv Immunol 2005;86:1-41.

42. Apasov SG, Blackburn MR, Kellems RE, Smith PT, Sitkovsky MV. Adenosine deaminase deficiency increases thymic apoptosis and causes defective T cell receptor signaling. J Clin Invest 2001;108:131-41.

43. Haghbin M, Rostami-Nejad M, Forouzesh F, Sadeghi A, Rostami K, Aghamohammadi E, et al. The role of CXCR3 and its ligands CXCL10 and CXCL11 in the pathogenesis of celiac disease. Medicine 2019;98:e15949.

44. Przybylska-Felus M, Piatek-Guziewicz A, Dynowski W, Zwolińska-Wcisło M, Rozpondek P, Mach T. Antibodies against alfa-enolase as an indication of inflammatory process in patients with celiac disease-preliminary results. Przegl Lek 2014;71:254-7.

45. Shao W, Yeretssian G, Doiron K, Hussain SN, Saleh MJ. The caspase-1 digestome identifies the glycolysis pathway as a target during infection and septic shock. J Biol Chem 2007;282:36321-9.

46. Stulík J, Hernychová L, Porkertová S, Pozler O, Tucková L, Sánchez D, et al. Identification of new celiac disease autoantigens using proteomic analysis. Proteomics 2003;3:951-6.

47. Terrier B, Degand N, Guitpina P, Servettaz A, Guillemin L, Mouthon L. Alpha-enolase: a target of antibodies in infectious and autoimmune diseases. Autoimmun Rev 2007;6:176-82.

48. Perconti G, Ferro A, Amato F, Rubino P, Randazzo D, Wolff T, et al. The kelch protein NS1-BP interacts with alpha-enolase/MBP-1 and is involved in c-Myc gene transcriptional control. Biochim Biophys Acta 2007;1773:1774-85.

49. Mosca M, Chimenti D, Pratesi F, Baldini C, Anzilotti C, Bombardieri S, et al. Prevalence and clinico-serological correlations of anti-alfa-enolase, anti-C1q, and anti-dsDNA antibodies in patients with systemic lupus erythematosus. J Rheumatol 2006;33:695-7.

50. Anderson VE, Weiss PM, Cleland WJB. Reaction intermediate analogs for enolase. Biochemistry 1984;23:2779-86.

51. Pontillo A, Di Toro N, Edomi P, Shadlow A, Ammadeo A, Gattorno M, et al. Anti-enolase Antibodies in Serum from Pediatric Patients Affected by Inflammatory Diseases: Diagnostic and Pathogenetic Insights. Int J Rheumatol 2011;2011.